PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00359008 |
Recruitment Status :
Completed
First Posted : August 1, 2006
Last Update Posted : January 15, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Age Related Macular Degeneration |
Study Type : | Observational |
Actual Enrollment : | 336 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV) |
Study Start Date : | July 2006 |
Actual Study Completion Date : | September 2007 |

Group/Cohort |
---|
1
Intermediate AMD
|
2
New untreated CNV subject
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with AMD related lesions:
Newly diagnosed (up to 6 months) non-treated CNV patients secondary to AMD in the study eye, or GA patients or Early and Intermediate AMD patients.
- Age ³ 50 for AMD patients
- VA with habitual correction in study eye 6/60 or better
- Mental and physical ability to perform a PHP/HPHP test
- Subject able and willing to sign consent form and participate in study
- Subject is not participating in another study when conducting the test
Exclusion Criteria:
-
Evidence of macular disease other than AMD or Glaucoma in the study eye.
- Presence of any significant media opacity that precludes a clear view of the macular area as identified by biomicroscopy, fundus photography, or fluorescein angiography in the study eye
- Any non-macular related ocular surgery performed within 3 months prior to the study in the study eye
- CNV patient inability to tolerate intravenous fluorescein angiography

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00359008
Israel | |
Ha'emek Hospital | |
Afula, Israel, 18101 |
Study Director: | Ofer Sharon, MD | Notal Vision |
Publications:
Responsible Party: | Osnat Ehrman, NotalVision |
ClinicalTrials.gov Identifier: | NCT00359008 |
Other Study ID Numbers: |
PHP V3 |
First Posted: | August 1, 2006 Key Record Dates |
Last Update Posted: | January 15, 2008 |
Last Verified: | January 2008 |
AMD CNV PHP |
Macular Degeneration Choroidal Neovascularization Neovascularization, Pathologic Retinal Degeneration Retinal Diseases |
Eye Diseases Metaplasia Pathologic Processes Choroid Diseases Uveal Diseases |